L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.48 NOK 3.01% Market Closed
Market Cap: 374.1m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LYTIX stock under the Base Case scenario is 2.52 NOK. Compared to the current market price of 5.48 NOK, Lytix Biopharma AS is Overvalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LYTIX Relative Value
Base Case
2.52 NOK
Overvaluation 54%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

33.5
P/S
P/S
Price to Sales
33.5
vs History
46
vs Industry
25
Median 3Y
33.3
Median 5Y
32.5
Industry
6.9
Forward
3.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-5.5
Industry
22.4
Forward
-1.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-5.1
Industry
19.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-5.1
Industry
23.2
More Details
3.5
P/B
P/B
Price to Book Value
3.5
vs History
38
vs Industry
9
Median 3Y
3.4
Median 5Y
3.1
Industry
2.5
More Details
22
EV/S
EV/S
Enterprise Value to Sales
22
vs History
53
vs Industry
22
Median 3Y
26.1
Median 5Y
24.4
Industry
7.5
Forward
2.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.9
Industry
4
Forward
-16.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.8
Industry
3.7
Forward
-16.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.5
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.5
Industry
3.4
More Details
22.8
EV/IC
EV/IC
Enterprise Value to IC
22.8
vs History
61
vs Industry
8
Median 3Y
27.3
Median 5Y
29.2
Industry
4.6
More Details

Multiples Across Competitors

LYTIX Competitors Multiples
Lytix Biopharma AS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Lytix Biopharma AS
OSE:LYTIX
373.5m NOK 33.5 -4 -2.6 -2.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 067 711 -166 671.6 -202 392.5 -200 083
US
Abbvie Inc
NYSE:ABBV
332B USD 5.9 78.3 15.5 23.4
US
Amgen Inc
NASDAQ:AMGN
148.1B USD 4.4 36.2 15 26.5
US
Gilead Sciences Inc
NASDAQ:GILD
123.2B USD 4.3 256.7 10.2 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.7B USD 10.1 -208.6 22.6 23.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 008.9 -512.6 -558.2 -543.3
AU
CSL Ltd
ASX:CSL
116B AUD 4.9 27.2 16.8 21
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.5B USD 4.3 13.9 8.5 9.4
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.3 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
33.3B EUR 17.2 45.2 -2 557.2 -1 714.5
P/S Multiple
Revenue Growth P/S to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average P/S: 3 188 165.8
33.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
35 067 711
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.3
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 008.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
6%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
17.2
39%
0.4
P/E Multiple
Earnings Growth PEG
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average P/E: 76.3
Negative Multiple: -4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 671.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.3
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.2
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
256.7
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -208.6 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.2
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
NL
argenx SE
XBRU:ARGX
45.2
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBITDA: 14.8
Negative Multiple: -2.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 392.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.5
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 557.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBIT: 19.5
Negative Multiple: -2.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 083 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.5
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
13%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 714.5 N/A N/A

See Also

Summary
LYTIX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LYTIX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LYTIX stock valuation using valuation multiples.
Wall Street Estimates
LYTIX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LYTIX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.